Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699.